ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 65 filers reported holding ASCENDIS PHARMA A/S in Q4 2017. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,012,661 | +436533.4% | 42,852 | +469.5% | 0.00% | +100.0% |
| Q4 2022 | $919 | -100.0% | 7,524 | -88.0% | 0.00% | -75.0% |
| Q3 2022 | $6,478,000 | -30.3% | 62,733 | -37.2% | 0.00% | -33.3% |
| Q2 2022 | $9,289,000 | -61.8% | 99,923 | -51.8% | 0.01% | -53.8% |
| Q1 2022 | $24,313,000 | +28.5% | 207,164 | +47.3% | 0.01% | +30.0% |
| Q4 2021 | $18,914,000 | -40.5% | 140,596 | -29.5% | 0.01% | -47.4% |
| Q3 2021 | $31,780,000 | +455.7% | 199,384 | +358.6% | 0.02% | +375.0% |
| Q2 2021 | $5,719,000 | -42.7% | 43,478 | -43.8% | 0.00% | -42.9% |
| Q1 2021 | $9,977,000 | -57.2% | 77,410 | -44.6% | 0.01% | -56.2% |
| Q4 2020 | $23,298,000 | +24.4% | 139,691 | +15.1% | 0.02% | -30.4% |
| Q3 2020 | $18,725,000 | -50.2% | 121,338 | -52.2% | 0.02% | -54.9% |
| Q2 2020 | $37,570,000 | +23.5% | 254,018 | -5.9% | 0.05% | -25.0% |
| Q1 2020 | $30,413,000 | -55.3% | 270,077 | -44.7% | 0.07% | -20.0% |
| Q4 2019 | $67,997,000 | -30.9% | 488,762 | -52.1% | 0.08% | -45.5% |
| Q3 2019 | $98,365,000 | -24.4% | 1,021,243 | -9.7% | 0.16% | -20.0% |
| Q2 2019 | $130,172,000 | -29.7% | 1,130,454 | -28.1% | 0.20% | -29.6% |
| Q1 2019 | $185,084,000 | +1508.4% | 1,572,509 | +756.1% | 0.28% | +1438.9% |
| Q4 2018 | $11,507,000 | -24.8% | 183,675 | -15.0% | 0.02% | -5.3% |
| Q3 2018 | $15,310,000 | -59.4% | 216,054 | -61.9% | 0.02% | -61.2% |
| Q2 2018 | $37,732,000 | -13.3% | 567,223 | -14.8% | 0.05% | -15.5% |
| Q1 2018 | $43,539,000 | +104.8% | 665,727 | +25.4% | 0.06% | +100.0% |
| Q4 2017 | $21,263,000 | +14.5% | 530,791 | +3.6% | 0.03% | +3.6% |
| Q3 2017 | $18,575,000 | +205.6% | 512,414 | +134.0% | 0.03% | +154.5% |
| Q2 2017 | $6,078,000 | +56.9% | 218,941 | +58.2% | 0.01% | +57.1% |
| Q1 2017 | $3,875,000 | -15.6% | 138,383 | -39.0% | 0.01% | -30.0% |
| Q4 2016 | $4,591,000 | +199.7% | 226,804 | +197.6% | 0.01% | +233.3% |
| Q3 2016 | $1,532,000 | +305.3% | 76,222 | +256.4% | 0.00% | +200.0% |
| Q2 2015 | $378,000 | -59.0% | 21,384 | -59.7% | 0.00% | -50.0% |
| Q1 2015 | $922,000 | – | 53,121 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |